<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475121</url>
  </required_header>
  <id_info>
    <org_study_id>1031. Retinoblastoma GALOP 2</org_study_id>
    <nct_id>NCT03475121</nct_id>
  </id_info>
  <brief_title>Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma</brief_title>
  <acronym>RbGALOP2</acronym>
  <official_title>GALOP II Protocol for the Treatment of Unilateral Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital JP Garrahan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital San Juan de Dios, Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Pereyra Rossell, Montevideo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital JP Garrahan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol provides guidelines for the management of non-metastatic unilateral
      retinoblastoma and introduces an innovative adjuvant therapy for higher risk patients based
      upon the results of the Grupo de America Latina de Oncologia Pediatrica (GALOP) I study.
      Conservative therapy will be not protocolized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-metastatic retinoblastoma undergoing enucleation will be staged using the
      American Joint Committee on Cancer (AJCC), version 8, Tumor, Node, Metastasis (TNM)- H system
      and the International Retinoblastoma Staging System (IRSS). IRSS stage I patients recognized
      as higher risk will be assigned for adjuvant therapy. Those with standard risk will not
      receive adjuvant therapy after enucleation. Higher risk patients are defined as those with
      pathological retrolaminar optic nerve invasion and-or any degree of scleral invasion (pT3b,
      pT3c, pT3d). Based on the results of the GALOP I protocol, they will receive a reduced dose
      adjuvant chemotherapy regimen with 3 cycles of alternating cyclophosphamide, vincristine and
      idarubicin alternating with another 3 cycles of carboplatin and etoposide. Six doses of
      intrathecal topotecan will be given. Patients presenting with severe buphthalmia (cT3c-cT3e)
      will receive neo-adjuvant therapy with the same intensive regimen but including a higher dose
      of carboplatin as per GALOP I protocol plus intrathecal topotecan and secondary enucleation
      followed by adjuvant chemotherapy for a total of 8 cycles. Stage II patients (pT4) will
      receive the same adjuvant regimen plus orbital radiotherapy (45 cGy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of extraocular relapses</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants experiencing extraocular relapse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of number of patients experiencing acute, chronic and fatal toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants experiencing treatment-related adverse effects and mortality as measured by CTCAE v4.0</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Unilateral Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Low Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Risk Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with buphthalmus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combination Chemotherapy plus Intrathecal Topotecan</intervention_name>
    <description>Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin</description>
    <arm_group_label>Higher Risk Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Higher Dose Combination Chemotherapy plus Intrathecal Topotecan</intervention_name>
    <description>GALOP I-based systemic adjuvant therapy plus intrathecal topotecan</description>
    <arm_group_label>Patients with buphthalmus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy</intervention_name>
    <description>GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm</description>
    <arm_group_label>Stage II Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Adjuvant Therapy</intervention_name>
    <description>Patients will not receive any adjuvant therapy after enucleation of the affected eye.</description>
    <arm_group_label>Low Risk Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of retinoblastoma confirmed at participating institutions

          -  Ophthalmological diagnosis of unilateral retinoblastoma in patients undergoing
             conservative therapy.

          -  No prior therapy for retinoblastoma

          -  Lansky Performance Scale greater or equal to 50

          -  Normal organ function in those patients assigned for chemotherapy

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with unilateral retinoblastoma and germline mutations of the Rb1 gene or
             family history for retinoblastoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillermo L Chantada, MD, PhD</last_name>
    <phone>5411-4122-6000</phone>
    <email>gchantada@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Sampor</last_name>
    <phone>5411-4122-6000</phone>
    <email>claudiasampor@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital JP Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <state>CF</state>
        <zip>C1245AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Cernadas, MD</last_name>
      <phone>541141226335</phone>
      <email>coordinacioninvestigacion@garrahan.gov.ar</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Chantada, MD, PhD</last_name>
      <phone>541141226000</phone>
      <email>gchantada@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Sampor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital JP Garrahan</investigator_affiliation>
    <investigator_full_name>Guillermo Chantada</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

